EMA to review persistence of side effects known to occur with quinolone and fluoroquinolone antibiotics
Review to focus on long-lasting effects mainly affecting musculoskeletal and nervous systems
The European Medicines Agency (EMA) is reviewing systemic and inhaled quinolone and fluoroquinolone antibiotics to evaluate the persistence of serious side effects mainly affecting muscles, joints and the nervous system. These side effects are of particular importance when the medicines are used for less severe infections.